248 related articles for article (PubMed ID: 22851268)
1. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Pharoah PD; Abraham J; Caldas C
J Natl Cancer Inst; 2012 Aug; 104(16):1263-4; author reply 1266-8. PubMed ID: 22851268
[No Abstract] [Full Text] [Related]
2. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Nakamura Y; Ratain MJ; Cox NJ; McLeod HL; Kroetz DL; Flockhart DA
J Natl Cancer Inst; 2012 Aug; 104(16):1264; author reply 1266-8. PubMed ID: 22851270
[No Abstract] [Full Text] [Related]
3. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Stanton V
J Natl Cancer Inst; 2012 Aug; 104(16):1265-6; author reply 1266-8. PubMed ID: 22851267
[No Abstract] [Full Text] [Related]
4. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
Kelly CM; Pritchard KI
J Natl Cancer Inst; 2012 Mar; 104(6):427-8. PubMed ID: 22395645
[No Abstract] [Full Text] [Related]
5. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
7. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Chlebowski RT; Col N
J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
[No Abstract] [Full Text] [Related]
8. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
9. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Gurwitz D; Newman W
J Natl Cancer Inst; 2008 Sep; 100(18):1331; author reply 1332-4. PubMed ID: 18780871
[No Abstract] [Full Text] [Related]
10. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.
Yazdi MF; Rafieian S; Gholi-Nataj M; Sheikhha MH; Nazari T; Neamatzadeh H
Asian Pac J Cancer Prev; 2015; 16(15):6783-7. PubMed ID: 26434912
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.
Rae JM; Regan M; Leyland-Jones B; Hayes DF; Dowsett M
J Clin Oncol; 2013 Jul; 31(21):2753-5. PubMed ID: 23775974
[No Abstract] [Full Text] [Related]
14. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Woods B; Veenstra D; Hawkins N
Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
[TBL] [Abstract][Full Text] [Related]
15. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
[TBL] [Abstract][Full Text] [Related]
16. Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
Johnston SR
Lancet; 2016 Feb; 387(10021):819-21. PubMed ID: 26686312
[No Abstract] [Full Text] [Related]
17. CYP2D6 genotype and tamoxifen response.
Rae JM; Goetz MP; Hayes DF; Ingle JN; Li L; Storniolo AM; Stearns V; Flockhart DA
Breast Cancer Res; 2005 Jul; 7(5):E6. PubMed ID: 16168100
[No Abstract] [Full Text] [Related]
18. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
Dizdar O; Harputluoglu H; Altundag K
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651; author reply 1651. PubMed ID: 18035222
[No Abstract] [Full Text] [Related]
20. Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
Health News; 2005 Dec; 11(12):13-4. PubMed ID: 16416553
[No Abstract] [Full Text] [Related]
[Next] [New Search]
